CRISPR Therapeutics’ Casgevy Revenue Growth Reaccelerates
The gene-editing company narrowed its quarterly net loss 56% to $91.2 million.
CRISPR Therapeutics (CRSP) said Casgevy revenue climbed 151% from a year earlier as the gene-editing therapy’s commercial rollout regained momentum.
Casgevy generated $76 million in second-quarter revenue, up 78% from $43 million in the first quarter. The sequential increase reversed a slowdown that had taken revenue down from $54 million in the fourth quarter of 2024.
The therapy’s eligible U.S. population expanded to children age 2 and older, adding about 5,500 patients. Casgevy was approved in 39 countries, and Germany secured reimbursement after a pricing agreement had awaited implementation in the prior quarter.
CRISPR stopped reporting Casgevy patient-throughput measures after saying more than 500 people had initiated treatment in the first quarter. The company had previously reported 64 infusions during 2024, including 30 in the fourth quarter, and 147 first cell collections.
Quarterly collaboration revenue was $10 million, compared with none a year earlier, while net collaboration expense declined to $40.3 million as CRISPR’s share of Casgevy revenue increased. The net loss narrowed from $208.5 million a year earlier, helped by acquired in-process research-and-development expense falling to $2.5 million from $96.3 million after prior-year costs tied to the Sirius agreement.
Cash, cash equivalents and marketable securities rose to $2.364 billion at June 30 from $1.976 billion at year-end, primarily because of $585.4 million in convertible-note proceeds, partly offset by operating expenses. Research-and-development expense declined to $67.2 million, while general and administrative expense fell to $17.6 million.
CRISPR also moved CTX340 and CTX460 into Phase 1 trials and initiated U.S. studies of CTX310. The company broadened the zugo-cel program with an autoimmune-neurology trial and a lymphoma combination study with Eli Lilly’s pirtobrutinib, while two in-vivo CAR-T approaches entered IND- and CTA-enabling work. Those programs widened the clinical pipeline as Casgevy’s expanding reach began translating into renewed revenue growth.